CD47 and breast cancer: In the 119 clinically validated breast cancer samples (Figure 1E–G), the coexpression of αvβ3 and CD47 (αvβ3+/CD47+, 0.61 ± 0.33) was more prevalent in tumor parenchymal cells (4′, 6‐diamidino‐2‐phenylindole+ (DAPI+)/CK+) compared to tumor mesenchymal cells (DAPI+/CK−, 0.30 ± 0.26) (p < 0.01, Student's t‐test).